A case of severe visual loss related to treatment with pembrolizumab for metastatic renal pelvic cancer
Despite its rarity, vision loss is a potential irAE in patients treated with ICIs, including pembrolizumab.
Authors
- Hiroki Tanaka (ORCID: https://orcid.org/0000-0002-5178-7777)
- Naoko Kawamura (ORCID: https://orcid.org/0000-0001-9517-7543)
- Yudai Ishikawa (ORCID: https://orcid.org/0000-0001-7118-5522)
- Naoki Inoue (ORCID: https://orcid.org/0009-0006-1788-5257)
- Mihoko Iitzuka
- Tetsuo Okuno
Institutions
- Tokyo Medical and Dental University (JP)
- JA Toride Medical Center (JP)
Publication Details
- Journal
- IJU Case Reports
- Published
- 2024-09-06
- DOI
- https://doi.org/10.1002/iju5.12784
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00